Search Results

The GEN-PROBE APTIMA® Assay for Neisseria gonorrhoeae is a target amplification nucleic acid probe test that utilizes target capture for the in vitro qualitative detection of ribosomal RNA (rRNA) from Neisseria gonorrhoeae (GC) to aid in the diagnosis of gonococcal urogenital disease using the TIGRIS® DTS® Automated Analyzer or semiautomated instrumentation as specified. The assay may be used to test the following specimens from symptomatic individuals: clinician-collected endocervical, vaginal and male urethral swab specimens; and female and male urine specimens. The assay may be used to test the following specimens from asymptomatic individuals: clinician-collected endocervical, vaginal swab specimens; patient-collected 'vaginal swab specimens; and female and male urine. The assay is also intended for use with the testing of gynecological specimens, from both symptomatic and asymptomatic patients collected in the PreservCyt® Solution and processed with the Cytyc ThinPrep® 2000 System.

Clearance of this premarket notification extends the clinical performance claims of the commercially available GEN-PROBE®APTIMA® Assay for Neisseria gonorrhoeae with the testing of gynecological specimens collected in the PreservCyt® Solution and processed with the Cytyc ThinPrep® 2000 System, for use on the TIGRIS® DTS® System. The ancillary kit for this application is commercially available as the GEN-PROBE APTIMA Specimen Transfer Kit. The components of the APTIMA Specimen Transfer Kit include: (1) a transport tube containing transport media with a penetrable cap and (2) specific instructions for use regarding decontamination and specimen processing procedures. The APTIMA Transfer Kit may only be used in conjunction with the APTIMA Assays.

This document describes the GEN-PROBE APTIMA Assay for Neisseria gonorrhoeae on the TIGRIS DTS System. The goal of the submission appears to be to expand the clinical performance claims of the existing assay to include gynecological specimens collected in PreservCyt Solution and processed with the Cytyc ThinPrep 2000 System, for use on the TIGRIS DTS System.

Here's the breakdown of the acceptance criteria and study information:

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria provided in the document are primarily related to agreement studies and analytical performance targets rather than explicit numerical thresholds for clinical sensitivity/specificity against a gold standard for the new use case (PreservCyt specimens on the TIGRIS DTS System). The clinical studies focus on demonstrating equivalence between the TIGRIS DTS System and previously validated DTS Systems.

Ask a specific question about this device

The APTIMA® Assay for Neisseria gonorrhoeae is a target amplification nucleic acid probe test that utilizes target capture for the in vitro qualitative detection of ribosomal RNA (rRNA) from Neisseria gonorrhoeae (GC) to aid in the diagnosis of gonococcal urogenital disease. The assay may be used to test the following specimens from symptomatic individuals: clinician-collected endocervical, vaginal and male urethral swab specimens; and female and male urine specimens. The assay may be used to test the following specimens from asymptomatic individuals: cliniciancollected endocervical and vaginal swab specimens; and patient-collected vaginal swab specimens and female and male urine specimens. The assay is also intended for use with the testing of gynecological specimens, from both symptomatic and asymptomatic patients, collected in the PreservCyt Solution and processed with the Cytyc ThinPrep 2000 System.

Clearance of this premarket notification extends the clinical performance claims of the commercially available GEN-PROBE APTIMA Assay for Neisseria gonorrhoeae to include PreservCyt liquid Pap specimens (collected and processed by the Cytyc ThinPrep 2000 Processor) as acceptable testing specimens. The ancillary kit formulated for this specific application is the commercially available GEN-PROBE APTIMA Specimen Transfer Kit. The components of the APTIMA Specimen Transfer Kit include: (1) a transport tube containing transport media with a penetrable cap and (2) specific instructions for use regarding decontamination and specimen processing procedures. The APTIMA Specimen Transfer Kit may only be used in conjunction with GEN-PROBE APTIMA Assays for the detection of Chlamydia trachomatis and/or Neisseria gonorrhoeae.

The provided document describes the GEN-PROBE APTIMA Assay for Neisseria gonorrhoeae, specifically its expanded indication for use with ThinPrep Specimens. The acceptance criteria and the study proving the device meets these criteria are detailed below.

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria for sensitivity and specificity are not explicitly stated as numerical targets in the document. However, the study results are presented as the "Summary of Clinical Performance Data" and indicate the device's performance attributes. The general expectation for such a diagnostic assay is high sensitivity and specificity. The reported performance is based on the clinical study.

2. Sample Sizes and Data Provenance

• Test Set Sample Size: 1,646 symptomatic and asymptomatic female subjects were evaluated in the clinical study. (Page 8)
• Data Provenance: The data was collected from a prospective multi-center clinical study (Page 8). The study subjects were enrolled from sites with GC prevalence ranging from 0.0% to 5.0% (Page 8). While the exact country of origin is not explicitly stated, the context of an FDA submission (K062440) for a device from "San Diego, California" implies the study was likely conducted in the United States.

3. Number of Experts and Qualifications for Ground Truth

The document does not mention the use of experts to establish ground truth for the clinical study.

4. Adjudication Method for the Test Set

The adjudication method used to establish the "patient infected status" (ground truth) for the clinical study was based on a reference standard involving two other tests:

• The APTIMA Combo 2 Assay (for Chlamydia trachomatis and Neisseria gonorrhoeae).
• The APTIMA GC Assay (performed on endocervical swab specimens). (Page 8)

The criteria were:

• Infected Patient Status: Both reference NAATs (APTIMA Combo 2 Assay and APTIMA GC Assay on endocervical swab) were required to be positive.
• Non-Infected Patient Status: At least one reference NAAT was required to be negative.
• Inconclusive: If an equivocal result was obtained from any one of the reference NAATs, the patient infected status was categorized as inconclusive, and these specimens were not included in sensitivity and specificity calculations. (Page 8)

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No MRMC comparative effectiveness study was mentioned. The study focuses on the performance of the device itself against a defined ground truth, not on human readers with or without AI assistance.

6. Standalone Performance

Yes, a standalone (algorithm only) performance study was performed. The clinical study directly evaluated the performance of the APTIMA GC Assay in PreservCyt liquid Pap specimens against a defined patient infected status (ground truth) derived from other laboratory tests, without human-in-the-loop performance described. (Page 8)

7. Type of Ground Truth Used

The ground truth used was based on a composite reference standard derived from the results of two other Nucleic Acid Amplification Tests (NAATs) – the APTIMA Combo 2 Assay and the APTIMA GC Assay – performed on endocervical swab specimens. Specifically, two positive reference NAATs defined an infected patient, and at least one negative defined a non-infected patient. (Page 8)

8. Sample Size for the Training Set

The document does not explicitly mention a separate "training set" or its sample size for model development. Diagnostic assays like this typically undergo extensive analytical validation to determine performance characteristics (e.g., limit of detection, specificity) and then clinical validation using a distinct clinical sample set. The analytical studies describe testing with various organisms and dilutions, which might be considered part of the development and refinement process, but not a formally delineated "training set" in the context of machine learning.

9. How Ground Truth for the Training Set Was Established

Since a distinct "training set" is not described, the method for establishing its ground truth is not provided. For the analytical studies (e.g., Limit of Detection, Analytical Specificity), organism concentrations were precisely controlled by direct comparison/dilution of clinical isolates or by spiking known concentrations of organisms/cells into samples. (Page 3-4)

Ask a specific question about this device

The APTIMA® Assay for Neisseria gonorrhoeae is a target amplification nucleic acid probe test that utilizes target capture for the in vitro qualitative detection of ribosomal RNA (rRNA) from Neisseria gonorrhoeae (GC) to aid in the diagnosis of gonococcal urogenital disease using the TIGRIS® DTS® Automated Analyzer or semi-automated instrumentation as specified. The assay may be used to test the following specimens from symptomatic individuals: clinician-collected endocervical, vaginal and male urethral swab specimens; and patient-collected female and male urine specimens. The assay may be used to test the following specimens from asymptomatic individuals: clinician-collected endocervical and vaginal swab specimens; and patient-collected vaginal swab specimens¹ and female and male urine specimens. ¹Patient-collected vaginal swab specimens are an option for screening women when a pelvic exam is not otherwise indicated. The vaginal swab specimen collection kit is not for home use.

Not Found

This document is a 510(k) clearance letter for the TIGRIS® DTS® GEN-PROBE® APTIMA Assay® for Neisseria gonorrhoeae. It confirms that the device is substantially equivalent to a legally marketed predicate device. However, this letter does not contain the detailed study results, acceptance criteria, or performance data that would typically be found in the actual 510(k) submission or a clinical study report.

Therefore, I cannot fulfill most of your request directly from this document. The information provided is primarily an FDA clearance letter and an "Indications for Use Statement."

Here's what I can extract and what is explicitly missing from the provided text:

Information Extracted from the Document:

• Device Name: TIGRIS® DTS® GEN-PROBE® APTIMA Assay® for Neisseria gonorrhoeae
• Intended Use: In vitro qualitative detection of ribosomal RNA (rRNA) from Neisseria gonorrhoeae (GC) to aid in the diagnosis of gonococcal urogenital disease, using specified specimens from symptomatic and asymptomatic individuals.
• Sample Types: Clinician-collected endocervical, vaginal, and male urethral swab specimens; patient-collected female and male urine specimens; patient-collected vaginal swab specimens.

Missing Information (Not provided in the document):

1. A table of acceptance criteria and the reported device performance: This document does not include a table of acceptance criteria or performance metrics (e.g., sensitivity, specificity, PPV, NPV). These would be in the original 510(k) submission.
2. Sample sizes used for the test set and the data provenance: No information on sample sizes or data provenance (country, retrospective/prospective) is present.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not mentioned. For an in vitro diagnostic (IVD) like this, the "ground truth" is typically established by well-characterized reference tests (e.g., culture, another FDA-approved NAAT), not by human experts adjudicating images.
4. Adjudication method for the test set: Not applicable in the traditional sense for an IVD diagnostic assay primarily detecting genetic material. The ground truth is usually determined by reference methods.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, and the effect size: Not applicable. This is an IVD assay, not an imaging device requiring human reader interpretation or assistance.
6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done: The device itself is a standalone assay. Its performance is measured directly against a reference standard.
7. The type of ground truth used: While not explicitly stated, for Neisseria gonorrhoeae detection, the ground truth for such an assay is typically established through culture or a comparator FDA-approved nucleic acid amplification test (NAAT). The document refers to "in vitro qualitative detection of ribosomal RNA," strongly suggesting laboratory-based reference methods.
8. The sample size for the training set: The concept of a "training set" as understood in machine learning (which this question implies) is generally not applicable to a traditional IVD chemical/molecular assay like this one. These assays are developed and validated using a series of laboratory experiments and clinical studies, but not typically "trained" in the AI sense.
9. How the ground truth for the training set was established: See point 8.

In summary, this document is an FDA clearance letter and does not contain the detailed technical and clinical study information required to answer most of your questions. That data would be found in the actual 510(k) submission that was reviewed by the FDA, but is not included in this publicly available letter.

Ask a specific question about this device

Ask a specific question about this device